Patents by Inventor Edward B. Holson

Edward B. Holson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
    Patent number: 8609706
    Abstract: The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: December 17, 2013
    Assignee: Infinity Discovery, Inc.
    Inventors: Alfredo C. Castro, Kristopher M. Depew, Michael J. Grogan, Charles W. Johannes, Edward B. Holson, Brian T. Hopkins, Gregg F. Keaney, Nii O. Koney, Tao Liu, David A. Mann, Marta Nevalainen, Stephane Peluso, Lawrence Blas Perez, Daniel A. Snyder, Thomas T. Tibbitts
  • Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
    Patent number: 8461191
    Abstract: One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: June 11, 2013
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Edward B. Holson, Brian T. Hopkins, Nii O. Koney, Daniel A. Snyder, Thomas T. Tibbitts
  • Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners
    Publication number: 20130131063
    Abstract: The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Application
    Filed: May 15, 2012
    Publication date: May 23, 2013
    Applicant: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Kristopher M. Depew, Michael J. Grogan, Charles W. Johannes, Edward B. Holson, Brian T. Hopkins, Gregg F. Keaney, Nii O. Koney, Tao Liu, David A. Mann, Marta Nevalainen, Stephane Peluso, Lawrence Blas Perez, Daniel A. Snyder, Thomas T. Tibbitts
  • Ansamycin formulations and methods of use thereof
    Patent number: 8357676
    Abstract: Provided herein, inter alia, are solid forms of geldanamycin analogs, pharmaceutical compositions comprising a geldanamycin analog and a crystallization inhibitor, methods of making and using such compositions. Additionally, provided are methods for the treatment of cancer, a neoplastic disease state and/or a hyperproliferative disorder, and methods of inhibiting Heat Shock Protein 90 (“Hsp90”).
    Type: Grant
    Filed: August 20, 2008
    Date of Patent: January 22, 2013
    Assignee: Infinity Discovery, Inc.
    Inventors: Brian C. Austad, Louis Grenier, Edward B. Holson, John J. Lee, Roger H. Pak, James R. Porter, James L. Wright
  • Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
    Patent number: 8304428
    Abstract: The present invention relates to heterocyclic compounds that bind to Bcl proteins and inhibit Bcl function, compositions comprising such compounds, and methods for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Grant
    Filed: April 2, 2010
    Date of Patent: November 6, 2012
    Assignee: Infinity Discovery, Inc.
    Inventors: Alfredo C. Castro, Michael J. Grogan, Edward B. Holson, Brian T. Hopkins, Nii O. Koney, Stephane Peluso, Daniel A. Snyder
  • Ansamycin formulations and methods of use thereof
    Patent number: 8283343
    Abstract: Amorphous, polymorphic, and solvated forms of 17-amino geldanamycin are disclosed. These compounds are particularly useful for the treatment of cancer, a neoplastic disease state and/or a hyperproliferative disorder, and inhibiting Heat Shock Protein 90 (“Hsp90”).
    Type: Grant
    Filed: August 20, 2008
    Date of Patent: October 9, 2012
    Assignee: Infinity Pharmaceuticals Inc.
    Inventors: Brian C. Austad, Louis Grenier, Edward B. Holson, John J. Lee, Roger H. Pak, James R. Porter, James L. Wright
  • Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
    Patent number: 8178690
    Abstract: The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: May 15, 2012
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Kristopher M. Depew, Michael J. Grogan, Charles W. Johannes, Edward B. Holson, Brian T. Hopkins, Gregg F. Keaney, Nii O. Koney, Tao Liu, David A. Mann, Marta Nevalainen, Stephane Peluso, Lawrence Blas Perez, Daniel A. Snyder, Thomas T. Tibbitts
  • Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners
    Publication number: 20110213145
    Abstract: The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Application
    Filed: April 19, 2011
    Publication date: September 1, 2011
    Applicant: Infinity Discovery, Inc.
    Inventors: Alfredo C. Castro, Kristopher M. Depew, Michael J. Grogan, Charles W. Johannes, Edward B. Holson, Brian T. Hopkins, Gregg F. Keaney, Nii O. Koney, Tao Liu, David A. Mann, Marta Nevalainen, Stephane Peluso, Lawrence B. Perez, Daniel A. Snyder, Thomas T. Tibbitts
  • Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners
    Publication number: 20110160259
    Abstract: One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Application
    Filed: November 30, 2010
    Publication date: June 30, 2011
    Applicant: Infinity Discovery, Inc.
    Inventors: Alfredo C. Castro, Edward B. Holson, Brian T. Hopkins, Nii O. Koney, Daniel A. Snyder, Thomas T. Tibbitts
  • Ansamycin formulations and methods of use thereof
    Patent number: 7947670
    Abstract: Provided herein, inter alia, are solid forms of geldanamycin analogs, pharmaceutical compositions comprising a geldanamycin analog and a crystallization inhibitor, methods of making and using such compositions. Additionally, provided are methods for the treatment of cancer, a neoplastic disease state and/or a hyperproliferative disorder, and methods of inhibiting Heat Shock Protein 90 (“Hsp90”).
    Type: Grant
    Filed: December 11, 2007
    Date of Patent: May 24, 2011
    Assignee: Infinity Pharmaceuticals Inc.
    Inventors: Brian C. Austad, Louis Grenier, Edward B. Holson, John J. Lee, Roger H. Pak, James R. Porter, James L. Wright
  • Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
    Patent number: 7928244
    Abstract: The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Grant
    Filed: August 21, 2007
    Date of Patent: April 19, 2011
    Assignee: Infinity Discovery, Inc.
    Inventors: Alfredo C. Castro, Kristopher M. Depew, Michael J. Grogan, Charles W. Johannes, Edward B. Holson, Brian T. Hopkins, Gregg F. Keaney, Nii O. Koney, Tao Liu, David A. Mann, Marta Nevalainen, Stephane Peluso, Lawrence B. Perez, Daniel A. Snyder, Thomas T. Tibbitts
  • Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
    Patent number: 7851637
    Abstract: One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: December 14, 2010
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Wei Deng, Kristopher M. Depew, Michael A. Foley, Christian C. Fritz, Asimina T. Georges Evangelinos, Michael J. Grogan, Nafeeza Hafeez, Edward B. Holson, Brian T. Hopkins, Nii O. Koney, Tao Liu, David A. Mann, Lisa A. Marcaurelle, Daniel A. Snyder, Dennis J. Underwood, Andrew A. Wylie, Lin-Chen Yu, Linping Zhang
  • Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
    Patent number: 7842815
    Abstract: One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Grant
    Filed: November 15, 2006
    Date of Patent: November 30, 2010
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Edward B. Holson, Brian T. Hopkins, Nii O. Koney, Daniel A. Snyder, Thomas T. Tibbitts
  • Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners
    Publication number: 20100190791
    Abstract: The present invention relates to heterocyclic compounds that bind to Bcl proteins and inhibit Bcl function, compositions comprising such compounds, and methods for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Application
    Filed: April 2, 2010
    Publication date: July 29, 2010
    Applicant: INFINITY PHARMACEUTICALS, INC.
    Inventors: ALFREDO C. CASTRO, MICHAEL J. GROGAN, EDWARD B. HOLSON, BRIAN T. HOPKINS, NII O. KONEY, STEPHANE PELUSO, DANIEL A. SNYDER
  • Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
    Patent number: 7745464
    Abstract: The present invention relates to heterocyclic compounds that bind to Bcl proteins and inhibit Bcl function, compositions comprising such compounds, and methods for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: June 29, 2010
    Inventors: Alfredo C. Castro, Michael J. Grogan, Edward B. Holson, Brian T. Hopkins, Nii O. Koney, Stephane Peluso, Daniel A. Snyder
  • Ansamycin formulations and methods of use thereof
    Publication number: 20090069281
    Abstract: Provided herein, inter alia, are solid forms of geldanamycin analogs, pharmaceutical compositions comprising a geldanamycin analog and a crystallization inhibitor, methods of making and using such compositions. Additionally, provided are methods for the treatment of cancer, a neoplastic disease state and/or a hyperproliferative disorder, and methods of inhibiting Heat Shock Protein 90 (“Hsp90”).
    Type: Application
    Filed: August 20, 2008
    Publication date: March 12, 2009
    Inventors: Brian C. Austad, Louis Grenier, Edward B. Holson, John J. Lee, Roger H. Pak, James R. Porter, James L. Wright
  • Ansamycin formulations and methods of use thereof
    Publication number: 20090062528
    Abstract: Provided herein, inter alia, are solid forms of geldanamycin analogs, pharmaceutical compositions comprising a geldanamycin analog and a crystallization inhibitor, methods of making and using such compositions. Additionally, provided are methods for the treatment of cancer, a neoplastic disease state and/or a hyperproliferative disorder, and methods of inhibiting Heat Shock Protein 90 (“Hsp90”).
    Type: Application
    Filed: August 20, 2008
    Publication date: March 5, 2009
    Inventors: Brian C. Austad, Louis Grenier, Edward B. Holson, John J. Lee, Roger H. Pak, James R. Porter, James L. Wright
  • Ansamycin formulations and methods of use thereof
    Publication number: 20080221077
    Abstract: Provided herein, inter alia, are solid forms of geldanamycin analogs, pharmaceutical compositions comprising a geldanamycin analog and a crystallization inhibitor, methods of making and using such compositions. Additionally, provided are methods for the treatment of cancer, a neoplastic disease state and/or a hyperproliferative disorder, and methods of inhibiting Heat Shock Protein 90 (“Hsp90”).
    Type: Application
    Filed: December 11, 2007
    Publication date: September 11, 2008
    Inventors: Brian C. Austad, Louis Grenier, Edward B. Holson, John J. Lee, Roger H. Pak, James R. Porter, James L. Wright